RedHill Biopharma Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $RDHL in the last 30 days.
See all $RDHL insider activity →RedHill Biopharma Ltd. (RDHL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Press Release RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota ® and Clenpiq ® , two established FDA-approved gastrointe
RedHill Biopharma reported H1 2026 results, highlighting a strategic portfolio reset. The company acquired commercial rights to Rebyota® and Clenpiq® for $12M, funded by the $18M sale of Talicia®. These FDA-approved GI drugs generated $37.5M in 2025 net sales. RedHill aims to grow revenues and expand its pipeline, with ongoing R&D in oncology and GI indications. The company's CEO emphasized improved liquidity and growth potential. (350 characters)
RedHill Biopharma (RDHL) acquired global rights to Rebyota and U.S. rights to Clenpiq from Ferring for $12M upfront, with royalties of 5-20%. The products had $37.5M combined U.S. sales in 2025. Ferring retains manufacturing, while RedHill handles commercialization. Success depends on sales growth and supply reliability.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning RDHL (RedHill Biopharma Ltd.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent RDHL coverage spans earnings, mergers & acquisitions and corporate actions.
The acquisition of Rebyota and Clenpiq adds two FDA‑approved GI products with $37.5M 2025 sales, likely boosting near‑term revenue and improving liquidity.
The acquisition expands RedHill's revenue base and improves liquidity, likely supporting upside pressure.
The deal adds GI products to RedHill's portfolio but economics depend on royalties and inventory commitments.
The licensing deal provides immediate revenue potential and long‑term royalty streams, which could improve RDHL's cash flow outlook.
The deal provides immediate cash and upside, likely supporting short‑term price momentum.
AlphAI scores every news story that mentions RDHL with an AI model for sentiment and relevance, and aggregates insider trades from RedHill Biopharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RedHill Biopharma Ltd. (RDHL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Press Release RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota ® and Clenpiq ® , two established FDA-approved gastrointe
2 min readRedHill Biopharma reported H1 2026 results, highlighting a strategic portfolio reset. The company acquired commercial rights to Rebyota® and Clenpiq® for $12M, funded by the $18M sale of Talicia®. These FDA-approved GI drugs generated $37.5M in 2025 net sales. RedHill aims to grow revenues and expand its pipeline, with ongoing R&D in oncology and GI indications. The company's CEO emphasized improved liquidity and growth potential. (350 characters)
3 min readRedHill Biopharma (RDHL) acquired global rights to Rebyota and U.S. rights to Clenpiq from Ferring for $12M upfront, with royalties of 5-20%. The products had $37.5M combined U.S. sales in 2025. Ferring retains manufacturing, while RedHill handles commercialization. Success depends on sales growth and supply reliability.
2 min readRedHill Biopharma (RDHL) acquired exclusive commercialization rights for Rebyota and Clenpiq from Ferring Pharmaceuticals, receiving $12M upfront. The deal expands RDHL's gastrointestinal drug portfolio. RDHL's P/S ratio is 0.64x, below its 10.8x historical median, indicating market skepticism. The company has a GF Score of 25/100, signaling financial and operational challenges, with a distress-level Altman Z-Score of -24.34.
2 min readRedHill Biopharma (RDHL) shares rose 64% after announcing the sale of its Talicia business to Apotex Health Corp. for $18M upfront and up to $35M in milestones. The stock traded at $1.08, up from a 52-week low of $0.57.
1 min readRedHill Biopharma (RDHL) sold its 70% stake in Talicia to Apotex (APTX) for $18M upfront and up to $35M in milestones. The deal strengthens RedHill's liquidity and funds its commercial expansion. Talicia treats H. pylori infections, a cause of gastric cancer and ulcers.
1 min readRedHill Biopharma completed a joint venture with Cumberland Pharmaceuticals on October 17, 2025, by selling a 30% equity stake in Talicia Holdings Inc. This deal involved Cumberland investing $4 million for joint control of THI, leading RedHill to deconsolidate THI operations and classify them as discontinued. RedHill has since filed unaudited pro forma financials to show the impact of this new financial structure and joint venture accounting on its historical results.
3 min read
